Boston biotech recruits Sanofi’s US cancer research chief; Syndax in-licenses Allergan portfolio
→Boston-based Silicon Therapeutics has recruited Sanofi’s US cancer R&D chief Christopher Winter to come over and run the R&D side of the business. Silicon has advanced new tech focused on physics-based simulations, chemistry and disease biology. This is just the latest in a long lineup of pharma investigators making their way to the biotech world.
→ Syndax $SNDX CEO Briggs Morrison has in-licensed a portfolio of preclinical, oral small molecule inhibitors of the interaction of menin with the mixed lineage leukemia protein from Vitae, a subsidiary of Allergan.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.